These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21815701)

  • 1. Trastuzumab in HER2-positive metastatic gastric cancer: profile report.
    Croxtall JD; McKeage K
    BioDrugs; 2011 Aug; 25(4):257-9. PubMed ID: 21815701
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.
    Sanford M
    Drugs; 2013 Sep; 73(14):1605-15. PubMed ID: 24057416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.
    Ikari N; Nakajima G; Taniguchi K; Sasagawa T; Narumiya K; Yamada T; Kudo K; Kitamura Y; Hayashi K; Nishikawa T; Yamamoto M
    Anticancer Res; 2014 Feb; 34(2):867-72. PubMed ID: 24511024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab: in HER2-positive metastatic gastric cancer.
    Croxtall JD; McKeage K
    Drugs; 2010 Dec; 70(17):2259-67. PubMed ID: 21080742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.
    Spackman E; Rice S; Norman G; Suh DC; Eastwood A; Palmer S
    Pharmacoeconomics; 2013 Mar; 31(3):185-94. PubMed ID: 23371465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells.
    Yoshida R; Tazawa H; Hashimoto Y; Yano S; Onishi T; Sasaki T; Shirakawa Y; Kishimoto H; Uno F; Nishizaki M; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2012 Nov; 61(11):1905-16. PubMed ID: 22465967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
    Koltz BR; Hicks DG; Whitney-Miller CL
    Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for gastric cancer--current status.
    Kulig J; Kołodziejczyk P; Kulig P; Legutko J
    J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer.
    Holden J; Garrett Z; Stevens A
    Lancet Oncol; 2011 Jan; 12(1):16-7. PubMed ID: 21249723
    [No Abstract]   [Full Text] [Related]  

  • 16. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.
    Luis M; Tavares A; Carvalho LS; Lara-Santos L; Araújo A; de Mello RA
    World J Gastroenterol; 2013 Oct; 19(38):6383-97. PubMed ID: 24151357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia.
    Choi JH; Han HS; Lee HC; Lee OJ; Kim JT; Lim SN; Lee KH; Kim ST
    Onkologie; 2011; 34(11):621-4. PubMed ID: 22104159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy and trastuzumab for HER2 positive gastric cancer].
    Tono Y; Yamada Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():577-81. PubMed ID: 25831826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.